F.L. Putnam Investment Management’s Zevra Therapeutics ZVRA Stock Holding History

F.L. Putnam Investment Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.27M	Buy	+350,501	New	+$3.16M	0.05%	197

Other funds holding ZVRA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

F.L. Putnam Investment Management's ZVRA Position: Q1 2026 in Review

F.L. Putnam Investment Management opened a new position in Zevra Therapeutics (ZVRA) in Q1 2026: 350,501 shares worth $3.27M. The stake represents 0.05% of the portfolio and ranks #197 among its holdings.

148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

F.L. Putnam Investment Management held 350,501 shares of Zevra Therapeutics worth $3.27M as of Q1 2026.
Zevra Therapeutics was a new F.L. Putnam Investment Management position in Q1 2026.
Zevra Therapeutics made up 0.05% of F.L. Putnam Investment Management's portfolio in Q1 2026, its #197 holding.
148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on F.L. Putnam Investment Management's 13F filing for Q1 2026, filed 5 May 2026.